Evidence item

The primary Nature Communications study reports 52% adjusted effectiveness for three doses among children aged 3–23 months and 88% among those aged 3–5 months. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 19468

Source: Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India · locator {} · excerpt hash sha256:a3e8730cfbfec52351246216a28de26b380789ee5bc82b4ffc73a33702d03bfa

For completed series (three doses), the aVE against hospitalization due to RVGE among children aged 3–23 months was 52% (95% CI, 32–66), with the highest aVE of 88% (CI, 53–97) observed among those aged 3-5 months.